HomeCompareEKTAY vs NOBL

EKTAY vs NOBL: Dividend Comparison 2026

EKTAY yields 2.22% · NOBL yields 2.14%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EKTAY wins by $23.3K in total portfolio value
10 years
EKTAY
EKTAY
● Live price
2.22%
Share price
$5.81
Annual div
$0.13
5Y div CAGR
33.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$46.1K
Annual income
$7,696.39
Full EKTAY calculator →
NOBL
NOBL
● Live price
2.14%
Share price
$106.01
Annual div
$2.27
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$22.8K
Annual income
$246.19
Full NOBL calculator →

Portfolio growth — EKTAY vs NOBL

📍 EKTAY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEKTAYNOBL
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EKTAY + NOBL cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
EKTAY pays
NOBL pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EKTAY
Annual income on $10K today (after 15% tax)
$189.12/yr
After 10yr DRIP, annual income (after tax)
$6,541.93/yr
NOBL
Annual income on $10K today (after 15% tax)
$182.19/yr
After 10yr DRIP, annual income (after tax)
$209.26/yr
At 15% tax rate, EKTAY beats the other by $6,332.67/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EKTAY + NOBL for your $10,000?

EKTAY: 50%NOBL: 50%
100% NOBL50/50100% EKTAY
Portfolio after 10yr
$34.5K
Annual income
$3,971.29/yr
Blended yield
11.52%
📊

Analyst Conviction Gap

Where Wall Street is split right now

EKTAY
Analyst Ratings
1
Hold
Consensus: Hold
Altman Z
1.3
Piotroski
4/9
NOBL
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EKTAY buys
0
NOBL buys
0
No recent congressional trades found for EKTAY or NOBL in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEKTAYNOBL
Forward yield2.22%2.14%
Annual dividend / share$0.13$2.27
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR33.3%0%
Portfolio after 10y$46.1K$22.8K
Annual income after 10y$7,696.39$246.19
Total dividends collected$22.9K$2.3K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: EKTAY vs NOBL ($10,000, DRIP)

YearEKTAY PortfolioEKTAY Income/yrNOBL PortfolioNOBL Income/yrGap
1← crossover$10,997$296.59$10,914$214.34+$83.00EKTAY
2$12,173$406.31$11,897$218.63+$276.00EKTAY
3$13,585$560.31$12,952$222.72+$633.00EKTAY
4$15,315$779.03$14,086$226.62+$1.2KEKTAY
5$17,481$1,094.10$15,302$230.33+$2.2KEKTAY
6$20,261$1,555.80$16,607$233.85+$3.7KEKTAY
7$23,925$2,246.38$18,007$237.18+$5.9KEKTAY
8$28,905$3,304.71$19,508$240.35+$9.4KEKTAY
9$35,902$4,973.85$21,116$243.35+$14.8KEKTAY
10$46,111$7,696.39$22,841$246.19+$23.3KEKTAY

EKTAY vs NOBL: Complete Analysis 2026

EKTAYStock

Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity, a MR-Linac technology; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; Elekta Synergy, a digital accelerator for advanced image-guided radiation therapy; treatment management solutions; automated and integrated quality assurance solutions; and hardware and software motion management technology. It also provides MOSAIQ Plaza for multidisciplinary cancer care; Elekta Axis Cloud, a managed hosting service; Elekta Studio, an image-guided brachytherapy solution; ImagingRing, a mobile CT scanner; Oncentra Brachy, a smart tool that facilitate repetitive tasks; Venezia applicator that enables the radiation oncologist to treat locally advanced cervical cancer; Elekta Flexitron afterloader for enabling the precise execution of all steps in the workflow; and Geneva, an applicator for cervical cancer treatment. In addition, the company offers Leksell Gamma Knife Icon for personalized radiation treatment; Leksell Gamma Knife Perfexion, a tool for neurosurgeons; Leksell Gamma Knife Lightning for accelerated radiosurgery. Further, it provides neurosurgery products comprising Leksell Vantage Stereotactic System for intracranial neurosurgery; and Leksell Stereotactic System or minimally invasive stereotactic neurosurgery. The company was incorporated in 1972 and is headquartered in Stockholm, Sweden.

Full EKTAY Calculator →

NOBLETF

The fund will invest at least 80% of its total assets in component securities of the index. The index contains a minimum of 40 stocks, which are equally weighted, and no single sector is allowed to comprise more than 30% of the index weight. It seeks to remain fully invested at all times in securities and/or financial instruments that, in combination, provide exposure to the returns of the index without regard to market conditions, trends or direction.

Full NOBL Calculator →
📬

Get this EKTAY vs NOBL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EKTAY vs SCHDEKTAY vs JEPIEKTAY vs OEKTAY vs KOEKTAY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.